RxDoctor Payments Data

John Peterson, MD

Infectious Disease · Mount Laurel, NJNPI 1447202270

Payments from drug & device makers

$368in general payments, 2019–2025

Across 5 payments — averaging $73.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$124
  • Paratek Pharmaceuticals, Inc.$101
  • Merck$98
  • Pharming Healthcare, Inc.$32
  • Gilead$13

What the payments were for

  • Food & beverage$33691%
  • Education$329%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$368 in reported general payments places this provider in the 40th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$190,041
Medicare patients
282
Services billed
2,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen44$206,251
RukobiaFostemsavir Tromethamine14$161,099
BiktarvyBictegrav/Emtricit/Tenofov Ala37$152,594
DescovyEmtricitabine/Tenofov Alafenam11$23,741
IsentressRaltegravir Potassium11$21,441
ErtapenemErtapenem Sodium17$11,141
Doxycycline Hyclate11$2,851
CeftriaxoneCeftriaxone Sodium35$1,757
Cefdinir12$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$13$382,58692 claims
Viiv Healthcare CompanyRukobia$124$161,09914 claims
MerckIsentress$98$21,44111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 334 infectious disease providers in New Jersey.

Other infectious disease in Mount Laurel

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →